Kory Lavine, MD
Advanced Heart Failure and Transplant Cardiology · Saint Louis, MONPI 1295990315
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $10,720 of the $11,848 with a category attached, or 90.5%. Kiniksa Pharmaceuticals, Ltd. accounts for 90.5% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2022 at $5,745 and has fallen 99.6% since, to $23 in 2025.
Across 34 payments — averaging $348.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Kiniksa Pharmaceuticals, Ltd.$11K
- Abbott$525
- Medtronic$225
- Abiomed$210
- Amgen$168
Across 13 payments — averaging $33,889 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$430K
- Novartis$6K
- Medtronic$4K
What the payments were for
- Consulting fees$10,72090%
- Food & beverage$1,12810%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Kiniksa Pharmaceuticals, Ltd. | 5 | $10,720 |
| Abbott | 19 | $525 |
| Medtronic | 4 | $225 |
| Abiomed | 3 | $210 |
| Amgen | 3 | $168 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARCALYST$10,720
- Impella$133
- HeartWare HVAD$133
- CARDIOMEMS$117
How this compares
$11,848 in reported general payments places this provider in the 60th percentile of 26 advanced heart failure and transplant cardiology providers in Missouri.
See all advanced heart failure and transplant cardiology providers in Missouri →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 13 | $19,721 |
| Tacrolimus | 51 | $7,199 |
| Sirolimus | 16 | $6,593 |
| EliquisApixaban | 11 | $6,364 |
| Mycophenolate Mofetil | 23 | $2,310 |
| Carvedilol | 100 | $816 |
| Pantoprazole Sodium | 39 | $552 |
| Rosuvastatin Calcium | 64 | $514 |
| Losartan Potassium | 65 | $440 |
| Metoprolol Succinate | 24 | $422 |
| Prednisone | 54 | $358 |
| Pravastatin Sodium | 20 | $316 |
| Omeprazole | 18 | $315 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 39 | $290 |
| Allopurinol | 23 | $239 |
Paid to pharmacies, not to this prescriber.
Other advanced heart failure and transplant cardiology in Saint Louis
- Gregory EwaldSaint Louis$35K
- Sumanth PrabhuSaint Louis$35K
- Nancy SweitzerSaint Louis$32K
- Justin HartupeeSaint Louis$30K
- Justin VaderSaint Louis$8K
- Jonathan MorenoSaint Louis$5K
- Amanda VermaSaint Louis$5K
- Ali JavaheriSaint Louis$4K
- Edward GeltmanSaint Louis$4K
- Joel SchillingSaint Louis$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.